Related Experiment Video
Updated: Jul 13, 2026

07:14
Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
Published on: July 11, 2025
Antiplasmodial compounds from Cassia siamea stem bark extract.
E O Ajaiyeoba1, J S Ashidi, L C Okpako
1Department of Pharmacognosy, University of Ibadan, Ibadan, Nigeria. e.ajaiyeoba@mail.ui.edu.ng
Phytotherapy Research : PTR
|August 21, 2007
Summary
Cassia siamea L. stem bark contains emodin and lupeol, effective against malaria parasites. These compounds show significant in vitro antimalarial activity, offering potential for new drug development.
Area of Science:
- Ethnobotany
- Pharmacology
- Medicinal Chemistry
Background:
- Cassia siamea L. is traditionally used in Nigerian ethnobotany for treating febrile illnesses.
- Plasmodium falciparum is a major cause of malaria, with increasing drug resistance.
- Identifying novel antimalarial compounds from natural sources is crucial.
Purpose of the Study:
- To investigate the antimalarial potential of Cassia siamea L. stem bark.
- To isolate and identify active compounds responsible for the antimalarial activity.
- To evaluate the in vitro efficacy of isolated compounds against Plasmodium falciparum.
Main Methods:
- Bioassay-guided fractionation of Cassia siamea L. stem bark extract.
- In vitro antimalarial activity testing using Plasmodium falciparum (K1 strain) and lactate dehydrogenase assay.
- Isolation of compounds using chromatographic techniques and structure elucidation via spectroscopy.
Main Results:
- Emodin and lupeol were successfully isolated from the ethyl acetate fraction.
- Both emodin and lupeol demonstrated significant antiplasmodial activity.
- The IC(50) values for emodin and lupeol were determined to be 5 microg/mL each.
Conclusions:
- Emodin and lupeol are the active compounds in Cassia siamea L. responsible for its antiplasmodial effects.
- These findings support the ethnobotanical use of Cassia siamea L. for febrile illnesses.
- The isolated compounds represent potential leads for the development of new antimalarial drugs.
Related Concept Videos
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
